Literature DB >> 1764378

Nucleolar organiser regions (AgNORs) as predictors in transitional cell bladder cancer.

P K Lipponen1, M J Eskelinen, S Nordling.   

Abstract

The predictive value of silver stained nucleolar organiser regions (AgNORs) was assessed in 229 patients with transitional cell bladder cancer followed up for over 10 years. The AgNORs were enumerated in pretreatment biopsy specimens. The AgNORs were related to clinical stage (T) (P = 0.0111), papillarity (P less than 0.0001), WHO grade (P less than 0.0001), DNA ploidy (P = 0.0010) and S-phase fraction (P less than 0.0001). Tumours presenting with pelvic lymph node involvement (P = 0.0085) or metastasis (P = 0.0780) at the time of diagnosis had more AgNORs than tumours confined to the bladder wall. Progression in T-, N- and M-categories (P = 0.0010-0.0030) was related to AgNORs and consequently they predicted bladder cancer related survival (P = 0.0005). The diploid tumours could be regrouped according to survival by AgNORs (P = 0.0001). In papillary tumours AgNORs predicted progression (P = 0.0110) and survival (P = 0.0038). In Ta-T1 tumours AgNORs predicted progression (P = 0.11) and survival (P = 0.0751) and also in T2-T3 tumours AgNORs contributed to survival significantly (P = 0.0039). The AgNORs subdivided WHO grade III tumours according to their ability to progress during the follow-up time (P = 0.0711). In a multivariate analysis AgNORs predicted progression independently in Ta-T1 category (P = 0.0165). AgNORs predicted recurrence free period like SPF (P = 0.0010). In conclusion, AgNORs are inferior to classic prognostic factors or DNA flow cytometric variables in muscle invasive bladder cancers whereas they have independent predictive value in superficial cancers.

Entities:  

Mesh:

Year:  1991        PMID: 1764378      PMCID: PMC1977863          DOI: 10.1038/bjc.1991.478

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  23 in total

1.  Relationship between DNA flow cytometric data, nuclear morphometric variables and volume-corrected mitotic index in transitional cell bladder tumors.

Authors:  P K Lipponen; M J Eskelinen; S Nordling
Journal:  Eur Urol       Date:  1991       Impact factor: 20.096

2.  A computer program for comparing K samples with right-censored data.

Authors:  E T Lee; M M Desu
Journal:  Comput Programs Biomed       Date:  1972-11

3.  Nucleolar organiser regions (NORs) in bladder cancer; relation to histological grade, clinical stage and prognosis.

Authors:  P K Lipponen; M J Eskelinen
Journal:  Anticancer Res       Date:  1991 Jan-Feb       Impact factor: 2.480

4.  Nucleolar organizer regions and prognosis in renal cell carcinoma.

Authors:  B Delahunt; J L Ribas; J N Nacey; P B Bethwaite
Journal:  J Pathol       Date:  1991-01       Impact factor: 7.996

5.  Lack of prognostic value of nucleolar organizer region enumeration in transitional cell carcinoma of the bladder.

Authors:  P Mansour; J Crocker; J Newman
Journal:  Arch Pathol Lab Med       Date:  1990-12       Impact factor: 5.534

6.  Prediction of superficial bladder cancer by histoquantitative methods.

Authors:  P K Lipponen; M J Eskelinen; M Sotarauta
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

7.  Nuclear morphometry in grading transitional cell bladder cancer compared with subjective histological grading.

Authors:  P Lipponen; M Eskelinen
Journal:  Anticancer Res       Date:  1990 Nov-Dec       Impact factor: 2.480

8.  Volume-corrected mitotic index and mitotic activity index in transitional cell bladder cancer.

Authors:  P K Lipponen; M J Eskelinen
Journal:  Eur Urol       Date:  1990       Impact factor: 20.096

9.  The role of nucleolar organiser regions as prognostic factors in breast cancer.

Authors:  M J Eskelinen; P K Lipponen; Y Collan; K J Syrjänen
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

10.  Relationship between DNA ploidy and survival in patients with exocrine pancreatic cancer.

Authors:  M Eskelinen; P Lipponen; Y Collan; S Marin; E Alhava; S Nordling
Journal:  Pancreas       Date:  1991-01       Impact factor: 3.327

View more
  8 in total

Review 1.  Nucleolar adaptation in human cancer.

Authors:  Leonard B Maggi; Jason D Weber
Journal:  Cancer Invest       Date:  2005       Impact factor: 2.176

2.  Predictive value of argyrophilic nucleolar-organizer-region-associated proteins in bladder cancer, using cell-imprint preparations.

Authors:  M Masuda; Y Takano; M Iki; S Jinza; S Noguchi; Y Kubota; M Hosaka
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

3.  Expression of MIB-1, mitotic index and S-phase fraction as indicators of cell proliferation in superficial bladder cancer. Finnbladder Group.

Authors:  T J Liukkonen; P K Lipponen; M Helle; H K Haapasalo; S Nordling; P Rajala
Journal:  Urol Res       Date:  1996

4.  Interphase argyrophilic nucleolar organiser regions and nucleolar counts in transitional cell bladder tumours.

Authors:  I A Korneyev; N N Mamaev; V V Kozlov; M G Rybakova; S H al-Shukri
Journal:  Mol Pathol       Date:  2000-06

5.  Analysis of Argyrophilic Nucleolar Organizer Regions (AgNORs) in Acute Leukemia in Adults.

Authors:  Małgorzata Gajewska; Elżbieta Rutkowska; Iwona Kwiecień; Piotr Rzepecki; Kazimierz Sułek
Journal:  Diagnostics (Basel)       Date:  2022-03-28

6.  Validation of silver-stained nucleolar organizer regions for evaluation of invasive character of urinary bladder carcinoma in rats and mice.

Authors:  H Iwata; T Otoshi; N Takada; T Murai; S Tamano; T Watanabe; Y Katsura; S Fukushima
Journal:  Urol Res       Date:  1995

7.  Cell proliferation indices, morphometry and DNA flow cytometry provide objective criteria for distinguishing low and high grade bladder carcinomas.

Authors:  A Pich; L Chiusa; A Comino; R Navone
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

8.  Prognostic factors in WHO grade 2 transitional-cell bladder cancer (TCC); a novel two-grade classification system for TCC based on mitotic index.

Authors:  P K Lipponen; M J Eskelinen; K Jauhiainen; E Harju; P Terho; H Haapasalo
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.